Brief Article
Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation

https://doi.org/10.1016/j.jtct.2023.01.025Get rights and content

Highlights

  • Pre-allogeneic hematopoietic stem cell transplantation (HSCT) donor/recipient Coronavirus disease 2019 (COVID-19) serostatus may impact post-HSCT serostatus.

  • Seropositive recipient-donor pairs had higher 1-month anti-S IgG titers than seronegative pairs.

  • A 3-month post-HSCT vaccination yielded higher 6-month titers in seropositive pairs.

  • Augmenting pre-HSCT immune response of donors and recipients may improve post-HSCT immunity.

ABSTRACT

The role of donor and recipient Coronavirus disease 2019 (COVID-19) immunologic status pre-transplantation has not been fully investigated in allogeneic hematopoietic stem cell transplantation (HSCT) recipients. Given the poor immunogenicity to vaccines in this population and the serious outcomes of COVID-19, adoptive transfer of immunity may offer important insight into improving protection for this vulnerable population. In this study, we evaluated the role of adoptive transfer of immunity at 1 month post-transplantation and 6 months post-transplantation after vaccination of recipients, based on pre-transplantation severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and infection exposures of both recipient and donor. Using banked specimens from related donor allogeneic HSCT recipients and clinical data from both donors and recipients, anti-Spike (S) IgG titers were analyzed at 1, 3, and 6 months post-transplantation according to prior SARS-CoV-2 immunologic exposures. Recipients were excluded if they had received SARS-CoV-2 monoclonal antibodies or had infection in the first 6 months post-transplantation. Of the 53 recipient-donor pairs, 29 donors and 24 recipients had prior SARS-CoV-2 immunologic exposure. Recipient-donor pairs with no prior SARS-CoV-2 exposure (D0R0) had significantly lower anti-S IgG titers at 1 month compared to those with prior exposures (D1R1) (D0R0: median, 2.43 [interquartile range (IQR), .41 to 3.77]; D1R1: median, 8.42; IQR, 5.58 to 12.20]; P = .008). At 6 months, anti-S IgG titers were higher in recipients who were vaccinated at 3 months post-transplantation in the D1R1 cohort (median IgG, 148.34; IQR, 92.36 to 204.33) compared with the D0R0 cohort (median IgG, 38.74; IQR, 8.93 to 119.71). Current strategies should be optimized to enhance SARS-CoV-2 protection for HSCT recipients, including augmentation of the immune response for both donors and recipients prior to transplantation.

Key Words

Adoptive transfer
SARS-CoV-2
humoral response
vaccine-induced immunity
HSCT

Cited by (0)

Abbreviations: SARS-CoV-2, severe acute respiratory syndromecoronavirus2; HSCT, Hematopoietic stem cell transplantation

Financial disclosure: See Acknowledgments on page 337.e5.

View Abstract